Announced
Completed
Synopsis
APRINOIA Therapeutics, a clinical-stage biotechnology company focused on neurodegenerative diseases, and Ross Acquisition II, a special purpose acquisition company, mutually terminated the $280m merger. The parties entered into a Termination Agreement on August 21, 2023, which is effective immediately and contains mutual releases for claims and liabilities.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.